GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Glenmark Pharmaceuticals Ltd.

NSE: GLENMARK | BSE: 532296 | ISIN: INE935A01035 | Industry: Pharmaceuticals
| Strong Performer, Getting Expensive

1860.1000 29.70 (1.62%)

NSE Jul 07, 2025 15:31 PM

New 52W High today

Volume: 1.1M

Glenmark Pharmaceuticals Ltd.

17 Aug 2023

1860.10

1.62%

Company Update

GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Glenmark Pharmaceuticals receives sANDA approval for Tacrolimus Ointment, 0.03%

More from Glenmark Pharmaceuticals Ltd.

Recommended

As IPO fever hits new high, Crizac and three other listings on the horizon

| 07 Jul 2025, 05:34PM

Market closes flat, Sharda Motor's board approves 1:1 bonus share allotment

Trendlyne Marketwatch | 07 Jul 2025, 03:55PM

Earnings Call Transcript - Q4FY20 for Glenmark Pharmaceuticals